Director/PDMR Shareholding

9 September 2015

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Director / PDMR Shareholding

Dechra Pharmaceuticals PLC ("the Company") has been notified that on9 September 2015 Ian Page, Chief Executive Officer, transferred 2,000 shares in the Company to his son, Andrew Page, for nil consideration.

The total beneficial holding of Ian Page following this transaction is unchanged, being 955,701 shares, which represents 1.086% of current issued share capital.

Rob Lamb, Company Secretary

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.